Cy Aaron Stein, M.D., Ph.D.
- Medical Oncology
- Prostate Cancer
- Prostate Cancer
The relief of human suffering and anxiety may be the most satisfying long-term thing a human being can do."
- Prostate Cancer
- Medical Oncology & Therapeutics Research
- 1982, Albert Einstein College of Medicine Bronx, NY, Awarded M.D.
- 1978, Stanford University, Stanford, CA, Ph.D., Organic Chemistry
- 1974, Brown University, Providence, RI, B.A
- 1985 - 1988, National Cancer Institute, Bethesda, Maryland
- 1983 -1985, Internal medicine resident, The New York Hospital-Cornell Medical Center, New York, NY
- 1982 -1983, Internal medicine intern, The New York Hospital-Cornell Medical Center, New York, NY
- California Medical License
- Maryland Medical License
- New York State Medical License
- 1986, Diplomate, American Board of Internal Medicine
- 1987, Diplomate, American Board of Oncology
Liu W, Bulgaru A, Haigentz M, Stein CA, Perez-Soler R, and Mani S. The bcl- 2-family of protein ligands as cancer drugs: The next generation of therapuetics. Curr. Med. Chem.-Anti-Cancer Agents, 2003 (3), 217-223.
Nichols G. and Stein CA. "Modulation of the activity of bcl-2 in Waldenstrom's Macroglobulinemia using antisense oligonucleotides" Semin. Oncol. 2003, (30) 297-299.
Wang L, Prakash R, Stein CA, Koehn R, and Ruffner D. "Progress in the Delivery of Therapeutic Oligonucleotides: Organ/cellular Distribution and Targeted Delivery of Oligonucleotides In Vivo", Antisense and Nucleic Acid Drug Development, 2003 (13) 169-189.
Cho-Chung Y, Gewirtz A, and Stein CA. (eds). Therapeutic Oligonucleotides. Ann. NY Acad Sci., 2003 (1002).
Stein CA, Dias N, Benimetskaya L, Jepsen J, Lai J and Raffo A. "LY900003 (Isis 3521) and G3139 (Genasense; Oblimersen)-Phosphorothioate Antisense Oligonucleotides With Pleotropic Mechanisms of Action." Nucleic Acid Therapeutics in Cancer, A. Gewirtz, ed., 2004, 171-191.
Stein CA, Mani S, and Benimetskaya L. "Combinations of Chemotherapy with Antisense Approaches Against bcl-2", in Combination Cancer Therapy: Modulators and Potentiators, G., Schwartz, ed., Humana Press, 2005, p. 207-228
Stein CA, Benimetskaya L and Mani S. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 7th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2005, p. 2891-2898.
Stein CA and Rossi J. "A Critical Assessment of the Potential of Short Interfering RNA Therapeutics', Drug Discovery Today: Technologies, 2005, www.drugdiscoverytoday.com; http://www.sciencedirect.com (2) 27-31.
Cho-Chung Y, Gewirtz A, and Stein CA. (eds). Therapeutic Oligonucleotides-Transcriptonal and Translational Strategies for Silencing Gene Expression. Ann. NY Acad Sci., 2005 (1058)
Benimetskaya L, Lai J, Khvorova A, Wu S, Miller P and Stein CA. "Induction of Apoptosis by G3139 in Melanoma Cells", Ann. NY Acad. Sci, 2005 (1058) 235-245.
Stein CA, Benimetskaya L, and Mani S. "Antisense Strategies for Oncogene Inactivation", Semin. Oncol. 2005, (32) 563-572.
Kornblum N, Ayyanar K, Benimetskaya L, Richardson P, Iacobelli M, and Stein CA. "Defibrotide, a Polydisperse Mixture of Single-Stranded Phosphodiester Oligonucleotides with Life-Saving Activity in Severe Hepatic Veno-Occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action", Oligonucleotides, 2006 (16), 105-114.
Stein CA. "The Genasense 'Learning Curve'", Letter to the Editor, Nature Biotechnology, 2007 (25) 972-973.
Stein CA. "Genasense: It Ain't Over Till the Fat Lady Sings", Editorial, Oligonucleotides, 2007 (17) 345-348.
Stein CA. Kornblum N, Lai J, and Benimetskaya L. "Genasense (G3139): An antisense Bcl-2 oligodeoxyribonucleotide with substantial clinical activity and a complex mechanism of action". In Therapeutic Oligonucleotides, J. Kurreck, ed., Biomolecular Science, Royal Society of Chemistry, 2008, p. 23-42.
Stein CA., Benimetskaya L, Kornblum N, and Mani S. "Antisense Agents", in Principles and Practice of Oncology, 8th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2008.
Stein CA and Colombini M. "Specific VDAC Inhibitors: Phosphorothioate Oligonucleotides" J. Bioenerg. Biomemb., 2008, 40:157-162.
Stein CA, Hoehn B and Rossi J. "Oligonucleotide Therapeutics" In Principles of Anticancer Drug Development, E. Garrett-Mayer, et al., eds. Springer Press, 2011, p. 565-587.
Stein CA and Soifer H. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 9th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2011.
Soifer H, Koch T, Hansen B, Hoeg A, Oerum H and Stein CA. "Silencing of Gene Expression by Gymnotic Delivery of Antisense Oligonucleotides" in M. Kaufmann and C. Klinger, eds., Functional Genomics: Methods and Protocols: Methods in Molecular Biology, 815:333-346 Springer Press, 2011.
Stein CA and Goel S. "Therapeutic Oligonucleotides-The Road Not Taken", invited commentary in Clinical Cancer Research, 2011, 17:6369-6372.
Twardowski P and Stein CA. "Beyond the Abstract-Direct regulation of androgen receptor activity in prostate cancer cells by potent CYP17 inhibitors". UroToday.com, July 2, 2012
Hu J, Hsu J, Bergerot P, Yuh B, Stein CA and Pal S. "Preoperative therapy for localized prostate cancer: A comprehensive overview", Maturitas, 2013, 74:3-9.
Pal S, Stein CA, and Sartor O. "Enzalutamide for the treatment of prostate cancer," Expert Opinion in Pharmacotherapy, 2013, (14), 679-685
Eroglu Z, Stein CA, Pal S. "Targeting angiopoietin-2 signaling in cancer therapy, Expert Opinion in Investigational Drugs, 2013, (22), 813-825.
- American Society for Clinical Oncology
- American Association for Cancer Research
- American Society for Gene Therapy (Oligonucleotide Therapeutics Committee, 2005-2008)